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5-Hydroxymethylcytosine (5hmC) is produced from 5-methylcytosine
(5mC) by Ten-eleven translocation (TET) dioxygenases. The epigenetic
modification 5hmC has crucial roles in both cellular development and dif-
ferentiation. The 5hmC level is particularly high in the brain. While 5mC is
generally associated with gene silencing/reduced expression, 5hmC is a
more permissive epigenetic mark. To understand its physiological function,
an easy and accurate quantification method is required. Here, we have
developed a novel LC-MS/MS-based approach to quantify both genomic
5mC and 5hmC contents. The method is based on the liberation of nucle-
obases by formic acid. Applying this method, we characterized the levels of
DNA methylation and hydroxymethylation in mouse brain and liver, pri-
mary hepatocytes, and various cell lines. Using this approach, we confirm
that the treatment of different cell lines with the DNA methyltransferase
inhibitor 5-aza-20-deoxycytidine leads to a decrease in 5mC content. This
decrease was accompanied by an increase in 5hmC levels in cell lines of
hematopoietic origin. Finally, we showed that ascorbate elevates the levels
of 5hmC and augments the effect of 5-aza-20-deoxycytidine without signifi-
cantly influencing 5mC levels.
In mammals, CpG dinucleotides are prone to become
methylated. CpG methylation plays important roles in
transcriptional gene silencing, genomic imprinting, and
X chromosome inactivation [1]. Methylation patterns
are established by the de novo methyltransferases
DNMT3A and DNMT3B. Existing methylation pat-
terns are preserved during cell divisions by the mainte-
nance DNA methyltransferase DNMT1. This enzyme
preferentially binds hemimethylated DNA (methylated
only on one strand) and consequently replicates the
parental DNA methylation to the newly synthesized
DNA strand. DNA demethylation can be executed by
demethylase enzymes [2]. DNA methylation is consid-
ered to be a reversible modification as methylation
patterns can be established de novo, maintained
through generations, or undergo dynamic changes
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genomewide or at specific loci, reflecting environmental
conditions [3–6].
Recently, the presence of another modified base,
5-hydroxymethylcytosine (5hmC), was discovered in
the central nervous system [7] and in other mam-
malian tissues [8]. 5hmC is a key metabolite in the
demethylation process. 5mC levels are fairly constant
in different tissues due to CpG methylation (4–5%
of all cytosines). In contrast, 5hmC levels are vari-
able with the highest level detected in brain (approxi-
mately 1% or more) and 10–100 times lower in
other cell types [7,8] or even lower in iPSCs (0.12%)
[4] or cell lines [9].
The DNA demethylase Ten-eleven translocation
(TET) enzymes are Fe2+- and a-ketoglutarate-depen-
dent oxidases, which efficiently convert 5mC into
5hmC both in vitro and in vivo [2]. Furthermore, TET
can further oxidize 5hmC to 5-formylcytosine (5fC)
and 5-carboxylcytosine (5caC) [10]. Accordingly, the
availability of a-ketoglutarate, a key molecule of the
citric acid cycle, can have significant consequences on
the epigenetic control of genome activity and thereby
has substantial impact on health and disease. Indeed,
recent studies have shown that the catalytic activity of
TET proteins is impaired due to mutations in the
isocitrate dehydrogenase (IDH) genes leading to the
formation of 2-hydroxyglutarate instead of a-ketoglu-
tarate in various tumors (reviewed in [11]). Ascorbate
was also reported to play a role in oxidative demethy-
lation of DNA. It is a substantial factor necessary for
the full catalytic activity of TET dioxygenases (DNA
demethylase) [12,13] and also of Jmjc histone demethy-
lases [14]; thus, it appears to be a mediator at the
interface between the genome and environment [15,16]
The role of ascorbate is the reduction of Fe3+ to
Fe2+, which is necessary for the catalytic activity of
these enzymes.
Several methods have been developed to detect
covalent DNA modifications (reviewed in [17]). Bisul-
fite conversion was set up for mapping 5mC nucleo-
tides, and it is accepted as the gold standard [18].
However, using this chemical conversion it is impossi-
ble to distinguish 5mC from 5hmC [19]. Affinity
enrichment methods are based on the immunoprecipi-
tation of fragmented genomic DNA with 5mC and
5hmC antibodies (MeDIP and hMeDIP) followed by
PCR or sequencing, and they are widely used for this
purpose. Another method to distinguish the two main
covalent DNA modifications is the specific glucosyla-
tion of 5hmC combined with MspI digestion, where
the glucosylated DNA sites are resistant to cleavage,
thus allowing single-nucleotide 5hmC mapping [20].
However, these methods are not sufficiently exact for
quantitative analysis [21].
An alternative approach for exact quantification of
DNA methylation is the highly reliable and simple
global genomic quantification by liquid chromatogra-
phy coupled with mass spectrometry (LC-MS/MS).
This is considered as the most accurate for simultane-
ously measuring global 5mC and 5hmC levels in
genomic DNA [4,8] after digesting the genomic DNA
into nucleotides by a multienzyme cocktail. We have
recently developed an alternative approach based on
the liberation of nucleobases by formic acid to quan-
tify genomic 5mC content. Using this method, we
have previously reported the highly dynamic nature
of DNA methylation [22]. Our aim here was to
improve this technique by developing genomic 5hmC
detection. Furthermore, we intended to investigate the
role of 5-aza-20-deoxycytidine on 5hmC levels in a
panel of human cell lines. The FDA-approved epige-
netic drug, 5-aza-20-deoxycytidine (5azadC or decita-
bine), is a potent methyltransferase inhibitor [23] that
reduces the level of 5mC in genomic DNA. Here, we
show that 5-aza-20-deoxycytidine treatment increases
5hmC levels in hematopoietic cells. Moreover,
cotreatment with decitabine and ascorbate allows a
decitabine-dependent increase in 5hmC levels in HeLa
cells.
Materials and methods
Cell culture
A375 melanoma, A2058 melanoma, HepG2 hepatocarci-
noma, HeLa cervix carcinoma, MES-SA uterine sarcoma,
H1650 bronchoalveolar carcinoma, HTR8 placenta,
BeWo choriocarcinoma, HL60 promyeloblast, and K562
lymphoblast cell lines were obtained from ATCC. They
were cultured either in Dulbecco’s modified Eagle’s med-
ium (A375, A2058, HeLa, MES-SA, and H1650 cells),
advanced MEM (HepG2 cells), or RPMI-1640 (HL60,
K562, and HTR8 cells) supplemented with 10% fetal
bovine serum (FBS), 1% glutamine, 1% penicillin/strepto-
mycin, or F-12 medium supplemented with 20% FBS
(BeWo cells). DT40 cells were cultured in RPMI-1640
medium (Gibco) supplemented with 7% FBS, 3%
chicken serum, 50 lM b-mercaptoethanol, and penicillin/
streptomycin. No ascorbate was added to the culture
media. Human iPSCs were differentiated into NPCs as
described in Ref. [24]. Briefly, iPSC-derived free-floating
embryoid bodies were treated with human recombinant
Noggin and DKK1, SB431542, and cyclopamine for
21 days. After rosette formation, NPCs were dissociated
and propagated using FGF2. This protocol gives rise to
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dorsal telencephalic neural progenitors that can be fur-
ther differentiated into PROX1 expressing dentate gyrus
granule cells.
Drug treatments
Cells were treated with vehicle (DMSO) or 1 lgmL1
5-aza-20-deoxycytidine for 48 h. When indicated, cells were
treated with 100 lgmL1 ascorbate (approx. 500 lM) for
48 h. Medium was changed after 24 h, and fresh medium
was also supplemented with the drugs used for the
treatments. DNA was extracted according to the Puregene
(158745; Qiagen, Hilden, Germany) protocol.
Animals and animal studies
C57BL/6J mice were derived from mice purchased from
The Jackson Laboratories. Mice were kept under routine
laboratory conditions in an approved animal facility. The
RCNS, Hungarian Academy of Sciences Institutional Ani-
mal Care and Use Committees approved the animal stud-
ies. Mouse liver and forebrain were taken out freshly from
the animals and frozen. Genomic DNA was prepared with
DNeasy Blood & Tissue Kit (Qiagen).
Primary mouse hepatocyte culture
A total of 12- to 16-week-old male C57BL/6 mice were
used. Primary mouse hepatocyte culture was prepared as
previously, except for the addition of the upper layer of
matrigel [25]. Briefly, mice were anaesthetized (20 mgkg1
tiletamine, 20 mgkg1 zolazepam, 12.5 mgkg1 xylazine,
and 3 mgkg1 butorphanol), and livers were perfused with
75 mL oxygenized perfusion buffer (120 mmolL1 NaCl,
5.4 mmolL1 KCl, 0.9 mmolL1 NaH2PO4, 26 mmolL1
NaHCO3, 5.6 mmolL1 glucose, pH 7.4) supplemented
with EGTA (0.5 mmolL1), followed by a second perfu-
sion with 75 mL perfusion buffer without EGTA. Collage-
nase digestion was performed by 75 mL perfusion buffer
supplemented with 2.5 mmolL1 CaCl2 and 0.2 mgmL1
collagenase (C5138, Sigma). The digested liver was taken
out of the abdominal cavity and minced using tweezers,
thereby releasing the hepatocytes. Cells were washed in ice-
cold sterile suspension buffer (10 mmolL1 HEPES,
142 mmolL1 NaCl, 7 mmolL1 KCl, pH 7.4), filtered
through a 100-lm mesh membrane and centrifuged for
4 min at 4 °C at 80 g. After one additional washing step,
dead cells were removed by Percoll (Sigma) centrifugation.
After checking their viability by trypan blue exclusion
staining, cells were seeded on 6-well plates precoated with
5 lgcm2 collagen I (BD, 356234) at a density of
0.5x106 cells/well in Williams E medium (Gibco) supple-
mented with hepatocyte thawing/plating supplement
(Gibco) and 10% FBS. Cells that did not attach were
removed by refreshing the culture medium after 1 h. 24 h
postseeding, the medium was renewed.
MS measurement
DNA was hydrolyzed to nucleobases by chemical means
using formic acid as described previously [26]. Briefly,
100 lL formic acid (100%) was added to 5–20 lL of samples
and pipetted into a 2-mL glass vial. The tightly crimped vial
was kept at 130 °C for 90 min. After nitrogen evaporation,
the samples were reconstituted in 80 lL of acetonitrile:wa-
ter:formic acid 49.5 : 49.5 : 1 solution and pipetted into a
200-lL microvial. Chemical standards such as dCTP,
5mdCTP, and 5hmdCTP were used to optimize the mass
spectrometer to get the highest sensitivity. A Sciex 6500
QTrap mass spectrometer equipped with turboV ion source
was used. Perkin Elmer Series200 system (consisting of bin-
ary pump, autosampler, and column oven) was used for sep-
aration. Water containing formic acid in 0.1% (eluent A)
and acetonitrile containing formic acid in 0.1% (eluent B)
was used for separation using gradient elution: A/B 30/70(1)-
4.5–90/10(1.5)-1.5-30/70(4.5). An Agilent RX-Sil column
(250 9 4.6 mm, 5um) was used for the separation. The flow
rate was 1 mLmin1. 40 lL of the samples was injected. The
column temperature was ambient, and samples were kept at
5 °C in the autosampler. Source conditions in mass spectro-
metric measurements were as follows: spray voltage 5000 V,
evaporation temperature: 500 °C, curtain, evaporation, and
drying gases 45, 45, and 50 instrument units, respectively.
50 ms dwell time and 5 ms pause times were used for each
MRM transitions. Collision energy was set to 30 eV.
Calibration
Calibration was performed on nucleotides. The same sam-
ple preparation protocol was applied as for the genomic
DNA. A ten-point calibration curve in the range of 1–10%
of mC and a nine-point calibration curve in the range of
0.01–1% of hmC relative to C were made by mixing the
individual nucleotide base solutions. Due to the high
dynamic range of the mass spectrometer, the relative con-
centration values were independent of the absolute amount
of nucleotides mixed. While the area ratios of 5mC/C and
5hmC/C were measured, the lowest calibration points were
not equal to the lowest limit of quantitation (LOQ). The
LOQ and limit of detection (LOD) values depend on the
absolute amount of 5hmC. This allowed us to use extrapo-
lated ratios based on relatively strong peaks for integration
even if the area ratios were out of the range.
Results and Discussion
We have developed a new HPLC-MS method to detect
5mC and 5hmC levels in the genome with liquid
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chromatography–mass spectrometry (LC-MS/MS).
The method uses formic acid to hydrolyze DNA to
nucleobases instead of enzymatic digestion often
described in the literature [4,8]. Although the retention
times of the nucleobases are close to each other, the
selectivity of MRM scan mode enables the LC-MS/
MS to detect them selectively according to their differ-
ent weights of molecular and fragment ions (Fig. 1A).
We have not investigated in the present study, but
with further improvements, formylcytosine and car-
boxylcytosine levels could be also detected in the gen-
ome by the same approach. The technique is
sufficiently sensitive to detect the low levels of 5hmC
found in the genome. Next, we examined the variabil-
ity of the MS measurement. To investigate this, geno-
mic DNA extracted from a C57BL/6 mouse liver was
divided into 21 identical samples. The samples were
measured by MS at three distinct time points to deter-
mine intraday and interday variabilities. Each day
seven parallels were measured. Fig. 1B shows the
intra- and interday variabilities of the MS measure-
ment detecting genomic 5mC/C and 5hmC/C ratios in
mouse liver. The coefficients of variation (SD/mean)
for intraday variability were 0.08 and 0.10, respec-
tively. Very similar interday coefficients of variation
were observed: 0.12 and 0.18, respectively. Although
small and similar intra- and interday variabilities were
determined for both 5hmC/C and 5mC/C measure-
ments, all the parallels of an individual experiment on
one cell type presented in this study were always pro-
cessed together from the beginning (treatment of the
cells) to the analysis of DNA methylation and hydrox-
ymethylation levels following MS detection.
Next, we investigated the genomic 5mC and 5hmC
levels in different types of cells and tissues. Fig. 2A
shows the detected genomic 5mC/C ratios. It has been
shown previously that the tissue-specific distribution of
5mC is relatively stable among different tissues, but it
is highly variable for 5hmC [8]. However, we have
observed very high 5mC/C ratios in mouse forebrain
(9,6%). This high level of DNA methylation probably
corresponds to the reported high level of non-CpG
methylation in brain [27,28]. We also observed a
slightly higher level of DNA methylation in murine
primary hepatocytes relative to the methylation level
detected in mouse liver samples, which was similar to
the previously reported values [29]. The difference
might be explained by the loss of nonhepatocyte cells
with lower methylation and/or by the hypermethyla-
tion of the primary hepatocytes in the culture condi-
tions. This potential de novo methylation might also
include non-CpG methylation, as de novo methyltrans-
ferases efficiently methylate CpA dinucleotides, as well
[30,31]. In addition, we observed relatively high
(approximately 6,5%) genomic 5mC/C ratios in
human-induced pluripotent stem cells (iPSCs) and
their derivatives, neuronal progenitor cells (NPCs).
This high level of DNA methylation is typical for
iPSCs [32]. A similar level of methylation was detected
in chicken DT40 B-cell lymphoma, while the immortal-
ized cancer cell lines (A375 human melanoma, A2058
human melanoma) contained less than 4% 5mC. The
highest genomic DNA methylation level was approxi-
mately three times higher than the lowest.
A much higher degree of variation of 5hmC levels
was detected in our array of cell lines and tissue sam-
ples (Fig. 2B). Almost a hundred-fold more 5hmC was
measured in the samples with the highest 5hmC level
compared to those with the lowest. In the mouse fore-
brain, we detected high 5hmC level with a 5hmC/C
ratio of 1.4%, which is similar to previous studies on
brain-derived cells [7]. In accordance with previous
reports, low level of 5hmC was detected in the genome
of adult mouse liver [8,9,33]. Here, we also show simi-
lar level of approx. 0.2% 5hmC/C for mouse primary
hepatocytes. The iPSCs had a clearly lower 5hmC level
than brain and liver cells. Furthermore, a striking dif-
ference of 5hmC levels was observed between immor-
talized cell lines and the samples mentioned above.
DT40, A2058, and A375 cells have low genomic
5hmC/C ratios (below 0.06%), confirming that cell cul-
ture conditions result in a dramatic reduction in global
5hmC levels [9]. As reported previously, differentiating
NPCs were also characterized by low 5hmC levels [34],
which was similar to that observed in the case of
immortalized cells. Altogether, these experiments
demonstrate the applicability of our newly developed
sensitive and simple method to quantify global 5hmC
levels.
5azadC is a molecule frequently used to inhibit
genomic DNA methylation for research purposes and
to treat myelodysplastic syndrome and AML in clinics.
A paradoxical increase in the 5hmC level in HL60
human promyeloblast cells upon decitabine treatment
has been recently reported [35]. The authors explained
their observation by the preferential demethylation of
hemimethylated relative to methylated DNA strands
by the TET enzymes. These strands appear during
replication and remain hemimethylated as a result of
the inability of the cells to remethylate them due to
decitabine treatment. However, the authors did not
test any cell types other than HL60. Therefore, to
assess whether the described phenomenon is ubiqui-
tous, the effect of the hypomethylating agent on 5hmC
level was investigated in a broader range of cell lines
in our next set of experiments by taking advantage of
587FEBS Open Bio 8 (2018) 584–592 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
B. Vet}o et al. 5azadC treatment raises 5hmC level in hematopoietic cells
the newly developed sensitive technique (Fig. 3). Cells
were selected to represent various tissues of origin
(hematopoietic, liver carcinoma, uterine carcinoma,
melanoma lung carcinoma, and choriocarcinoma). As
seen previously, they exhibited variable but mostly low
(below 5%) methylation and very low (below 0.05%)
5hmC levels. We have chosen a 48-h treatment to
increase the number of cells undergoing division and
the amount of hemimethylated DNA strands in the
population investigated. As expected, treatment with
the DNA methyltransferase inhibitor 5azadC resulted
in systematic and significant decrease in 5mC levels.
Upon the 48-h treatment, 5mC/C ratios diminished to
approximately 50% compared to vehicle-treated cells
(Fig. 3A). When we looked at the effect of 5azadC
first, we could confirm that the treatment results in a
paradoxical increase in 5hmC level in HL60 cells ele-
vating the initial level of 0.05% to 0.12% (Fig. 3B).
However, it is necessary to emphasize that the 5mC
decrease is much greater than 5hmC increase, as the
most important part of 5mC loss is due to the absence
of remethylation on the newly synthetized strands and
only a small part could be attributed to the TeT activ-
ity at hemimethylated loci. Furthermore, 5hmC is less
stable and can eventually become further oxidized to
other cytosine derivatives, such as carboxylcytosine,
formylcytosine, or cytosine [8].
Interestingly, we found that the paradoxical effect of
5azadC on 5hmC levels was only detectable in
hematopoietic cells. For instance, in HepG2 cells we
could not detect any quantitative 5hmC change. Sur-
prisingly, in other cells of hepatic origin (Huh7)
5azadC treatment was shown to lead to reorganize
nuclear 5hmC by immunostaining [36]. In the case of
BeWo choriocarcinoma, 5azadC treatment resulted in
significant loss of genomic 5hmC level. However, we
found that the initial observation reported in the liter-
ature showing that decitabine treatment leads to
increased 5hmC/C ratios was characteristic of
hematopoietic cells we investigated. In addition to
HL60 human promyeloblast cells, K562 human myel-
ogenous leukemia and DT40 chicken lymphoblastoma
cells also showed significantly increased 5hmC levels
upon 5azadC treatment (P < 0.05, t-test) (Fig. 3). This
might suggest that a particular mechanism specific to
the hematopoietic cells is responsible for the observed
phenomenon. One can hypothesize that expression
levels of TeT genes are different in these cells than in
the others. It is a conceivable hypothesis that the
expression levels of TeT genes are higher in
Fig. 1. Detection of cytosine derivatives (C, 5mC, and 5hmC) by LC-MS/MS. Peak intensities from genomic DNA (A) Note the difference of
scale. Intra- and interday variability (B). Genomic 5mC/C and 5hmC/C ratios (%) in mouse liver are detected by MS. Error bars indicate SD
n = 8.
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hematopoietic cells per se. Alternatively, originally low
TeT expression levels could be highly increased upon
treatment. However, based on publicly available data
(proteinatlas.org [37]) none of these seems to be the
case. Although K562 cells seem to have high TeT1
expression, they have moderate TeT2 and TeT3
expression levels. HL60 cells have higher TeT2 and
TeT3 expression level accompanied with lower TeT1
level. These expression levels were not dramatically dif-
ferent from those of other cells tested in our panel. In
particular, BeWo cells had similar expression to K562
with a markedly different effect of 5azadC on their
5hmC levels. Similarly, other related gene expression
levels (IDH1 and IDH2 responsible for the synthesis
of a-ketoglutarate or DNMTs) do not allow establish-
ing an obvious correlation between the effect of
5azadC on 5hmC levels in hematopoietic cells and the
absence of the effect in cells of different origin.
We therefore hypothesized that the lack of clear
effect of 5azadC on 5hmC level is due to the different
oxidative balance in the cells. This might lead to very
low activity of TeT enzymes in some cells due to their
inability of efficiently reducing Fe3+ back to Fe2+ at
the end of the catalyzed reaction. As stated above,
ascorbate was reported to regulate DNA methylation
as a substantial cofactor for the full catalytic activity
of TET dioxygenases by reducing back Fe3+ to Fe2+
[12,13]. Therefore, the effect of ascorbate was investi-
gated. Plasma ascorbate concentration was reported to
be between 50 and 100 or as high as 200 lmolL1
[38–40]. As ascorbate has a short half-life, we used a
100 lgmL1 (approx. 500 lM) concentration in our
experiments. Here, we show that ascorbate treatment
of human HL60 and HeLa cells did not induce global
DNA methylation changes. Furthermore, cotreatment
of the same cells with ascorbate and decitabine did not
cause a greater 5mC decrease than decitabine alone.
However, the global 5hmC levels became significantly
elevated in our experiments on the tested human
hematopoietic cells upon ascorbate treatment (Fig. 4A
and B). This increase was much more robust than that
observed upon 5azadC treatment alone, indicating that
the two molecules have synergistic effect, and suggests
that even in HL60 cells ascorbate is not present at suf-
ficient level for the full activity of the TeT enzymes.
Furthermore, we could demonstrate the increase in
5hmC levels upon 5azadC treatment in HeLa cells
Fig. 2. Genomic 5mC/C (A) and 5hmC/C (B) ratios (%) in cell lines,
primary cells, and tissues. No ascorbate was added to the culture
media. Error bars indicate SD n = 4–6. [Corrections added after
online publication on 28 February 2018: y-axis of part (B) amended
to 5hmC]
Fig. 3. Genomic 5mC/C (A) and 5hmC/C levels (B) detected by
LC-MS upon 5-aza-20-deoxycytidine treatment. Black and white
columns indicate vehicle and 5-aza-20-deoxycytidine treatment,
respectively. No ascorbate was added to the culture media. Error
bars indicate SD P < 0.05. n = 3–5. [Corrections added after online
publication on 28 February 2018: y-axis of part (B) amended to 5hmC]
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only in the presence of ascorbate. Altogether, these
data suggest that some cell lines do not have function-
ally fully active TeT enzymes and are therefore unable
to respond to decitabine treatment by 5hmC increase
probably due to a scarcity of ascorbate.
Our data reported here demonstrate that decitabine
treatment reduces global 5mC and increases 5hmC
levels in different cells, particularly those originating
from hematopoietic malignancies. There is increasing
evidence that DNA hydroxymethylation and TET2
function is highly dysregulated in hematologic malig-
nancies (T-ALL, AML, CML), suggesting that TET
proteins can act as tumor suppressors (reviewed in
[41]). Indeed, the expression level of TeT2 positively
correlated with tumor-free survival according to a
recent study in CLL patients [42]. Our data suggest
that decitabine treatment in patients with hematopoi-
etic tumors might simultaneously lead to DNA
demethylation and increased 5hmC levels, the latter
playing a putative positive role in the therapeutic
effect of the drug. Recent data suggest that decitabine
could also be used efficiently in solid tumors alone or
in a combination therapy (for a recent review [43]).
In these cases, gene-specific DNA methylation
changes were considered due to the treatment, but
global effects and potential normalization of 5hmC
level might also play a role in the molecular action
of the drug. Our results also raise the possibility that
cotreatment with dietary ascorbate and decitabine
might lead to an increased effect and thereby an
increased overall survival in hematopoietic, or poten-
tially in other malignancies.
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